Zacks Small-Cap Research
Sponsored – Impartial - Comprehensive

August 27, 2021
David Bautz, PhD
312-265-9471
dbautz@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Chicago, IL 60606

Antibe Therapeutics Inc.

(OTCQX: ATBPF)

ATBPF: Awaiting Update on Otenaproxesul Following AME Study Pause…

Based on our probability adjusted DCF model that takes into account potential future revenues from otenaproxesul, ATBPF is valued at $4.75 per share. This model is highly dependent upon continued clinical success of otenaproxesul and will be adjusted accordingly based upon future clinical results and the company's execution.

Current Price (08/27/2021)	$0.98
Valuation	**$4.75**

OUTLOOK

On August 17, 2021, Antibe Therapeutics Inc. (ATBPF) announced financial results for the first quarter of fiscal year 2022 and provided a business update. Earlier this month, the company paused the absorption, metabolism, and excretion (AME) study of otenaproxesul due to a pre-specified safety threshold being exceeded. A total of 42 subjects were enrolled to receive daily doses of 75 mg or 100 mg of otenaproxesul, with 35 completing the 28-day administration period and seven completing 21 days of administration. Three subjects from the 100 mg cohort experienced liver transaminase elevations >5X the upper limit of normal. Antibe is collecting and analyzing additional data and will provide an update in October 2021 when the work is expected to be completed.

SUMMARY DATA

52-Week High	**$5.54**
52-Week Low	**$0.81**
One-Year Return (%)	**-67.33**
Beta	**0.51**
Average Daily Volume (sh)	**112,910**
Shares Outstanding (mil)	**52**
Market Capitalization ($mil)	**$51**
Short Interest Ratio (days)	**1**
Institutional Ownership (%)	**0**
Insider Ownership (%)	**N/A**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using #Lin Estimate	**N/A**
P/E using #Lin Estimate	**N/A**

Risk Level	**Above Avg.**
Type of Stock	**Small-Value**
Industry	**Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue

(In millions of $)

	Q1 (Jun)	Q2 (Sep)	Q3 (Dec)	Q4 (Mar)	Year (Mar)
2021	0.9 A	2.2 A	2.2 A	2.2 A	7.7 A
2022	2.2 A	2.2 E	2.2 E	2.2 E	8.8 E
2023					9.0 E
2024					9.2 E

Earnings per Share

	Q1 (Jun)	Q2 (Sep)	Q3 (Dec)	Q4 (Mar)	Year (Mar)
2021	-$0.12 A	-$0.16 A	-$0.13 A	-$0.02 A	-$0.56 A
2022	-$0.10 A	-$0.10 E	-$0.10 E	-$0.11 E	-$0.41 E
2023					-$0.38 E
2024					-$0.36 E

WHAT'S NEW

Business Update

Phase 3 Program for Otenaproxesul on Pause

On August 3, 2021, Antibe Therapeutics, Inc. (ATBPF) announced that the absorption, metabolism, and excretion (AME) study of otenaproxesul has been paused due to a pre-specified safety threshold being exceeded. The study had enrolled a total of 42 subjects that were randomized to receive either 75 mg or 100 mg of otenaproxesul daily, of whom 35 had completed the full 28 days of dosing and seven had completed 21 days of dosing. Following completion of the 28-day administration period, three of the subjects in the 100 mg cohort exhibited liver transaminase levels that were >5X the upper limit of normal (ULN), which is what triggered the pause in the trial.

The news of liver transaminase elevations is very unexpected as this was not previously seen in any of the long-term animal toxicology studies. And while the liver transaminase elevations are concerning, there were no elevations in other liver tests, thus there are no Hy's Law concerns. In addition, none of the patients with elevated liver transaminase levels had any signs of clinical illness and all were asymptomatic.

Since all subjects in the study were housed at the clinical research center for the entire duration of dosing any outside influences that could have affected liver transaminase levels can be ruled out, thus pointing to a drug-specific phenomenon. However, the only patients with large increases in liver transaminase levels were in the 100 mg cohort, thus it also appears as though it is a dose-dependent effect.

The study has a pre-specified 14-day post-administration observation period. The company is continuing to analyze blood samples from all study subjects during the observation period to determine the extent of the liver transaminase increases, including their duration. In addition, the level of COX inhibition will be examined through biomarkers such as TxB2 and PGE_2. Following the completion of the observation period, Antibe will evaluate all of the available data from the study in an effort to better understand the cause of the liver transaminase elevations. The company will also be requesting a meeting with Health Canada regarding the development path for otenaproxesul once all of the data has been collected and analyzed. The timing of this meeting is still not known; however, it is possible it could occur before the end of 2021.

While the future of otenaproxesul is currently uncertain, we believe there is still a potential path forward for the program. We anticipate the company approaching Health Canada with a plan to perform an additional AME study testing lower doses of the drug, which may also include a 75 mg cohort (assuming no liver transaminase elevations are seen in that cohort during the current observation period). As a reminder, the results of the Phase 2b efficacy trial showed that the 150 mg dose of otenaproxesul had robust efficacy in the primary endpoint and missed being statistically significant due to that arm of the trial not being properly powered. Thus, a lower dose may still offer sufficient efficacy, however that dose would have to be less than 100 mg (with additional insight into this possibility being obtained from the COX inhibition data). Ultimately, the path forward for otenaproxesul will not be determined until after the company is able to meet with Health Canada, thus we don't anticipate any clarity until that meeting is able to occur.

Financial Update

On August 13, 2021, Antibe announced financial results for the first quarter of fiscal year 2022 that ended June 30, 2021. The company reported revenues of CAD$2.7 million for the three months ending June 30, 2021 compared to revenues of CAD$1.1 million for the three months ending June 30, 2020. Sales were higher due to the impact of COVID-19 on the prior year's results.

General and administrative, selling and marketing, research and development, stock-based compensation, and amortization and depreciation totaled CAD$7.4 million for the first quarter of fiscal year 2022 compared to CAD$5.3 million for the first quarter of fiscal year 2021. The increase was primarily related to the following:

- G&A expenses decreased slightly to CAD$1.6 million in 1QFY22 due to decreased professional and consulting fees partially offset by increased salaries and wages, office, and other expenses.
- Selling and marketing costs were CAD$0.7 million in 1QFY22 compared to CAD$0.4 million in 1QFY21. The increase was due to higher salaries, commissions, travel, and entertainment costs.

- R&D expenses were CAD$3.2 million in 1QFY22 compared to CAD$2.1 million in 1QFY21. The increase was primarily due to higher salaries, professional and consulting fees, and research and clinical trial costs.
- Stock-based compensation in 1QFY22 was CAD$1.8 million compared to CAD$1.0 million in 1QFY21 due to expensing of previously granted RSUs.
- Amortization and depreciation was CAD$0.1 million in both 1QFY21 and 1QFY20.

As of June 30, 2021, Antibe reported cash and cash equivalents of approximately CAD$66.8 million, which we estimate is enough to fund operations for at least two years. As of June 30, 2020, Antibe had approximately 51.6 million shares outstanding and, when considering stock options and warrants, a fully diluted share count of approximately 64.0 million shares.

Conclusion

We await an update from the company regarding the future of otenaproxesul in October 2021 once the company has completed analyzing the data that should help to give a clearer picture of the cause and implications for the pause of the AME trial. As we await an update from the company we have made no changes to our model and our valuation remains at $4.75 per share.

PROJECTED FINANCIALS

Antibe Therapeutics Inc.
Income Statement

Antibe Therapeutics, Inc. Year Ends Mar. 31 / in US Dollars	FY 2021 A	Q1 '22 A	Q2 '22 E	Q3 '22 E	Q4 '22 E	FY 2022 E	FY 2023 E	FY 2024 E
Otenaproxesul	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
ATB-352 (royalty)	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Citagenix	$7.7	$2.2	$2.2	$2.2	$2.2	$8.8	$9.0	$9.2
Licensing / Development	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Total Revenues	$7.7	$2.2	$2.2	$2.2	$2.2	$8.8	$9.0	$9.2
YOY Growth	*2.4%*	*130.6%*	*-1.0%*	*0.3%*	*-0.9%*	*14.6%*	*2.5%*	*1.8%*
Cost of Goods Sold	$4.9	$1.3	$1.4	$1.4	$1.4	$5.6	$5.7	$5.7
Product Gross Margin	*36.5%*	*39.7%*	*35.7%*	*35.7%*	*35.7%*	*36.7%*	*36.8%*	*37.9%*
SG&A	$5.7	$1.3	$1.9	$2.0	$2.1	$7.2	$7.7	$7.9
R&D	$10.6	$2.5	$2.6	$2.8	$3.0	$10.9	$11.1	$11.9
Selling and marketing	$2.1	$0.5	$0.5	$0.5	$0.5	$2.0	$1.9	$1.9
Stock-based compensation	$3.2	$1.4	$0.8	$0.8	$0.8	$3.8	$3.2	$3.2
Impairment of goodwill	$0.4	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Amortization and Depreciation	$0.4	$0.1	$0.1	$0.1	$0.1	$0.3	$0.4	$0.4
Operating Income	($19.5)	($5.0)	($5.1)	($5.3)	($5.6)	($21.0)	($20.9)	($21.7)
Operating Margin	-254%	-232%	-230%	-239%	-254%	-239%	-232%	-237%
Interest Income / Net	($0.0)	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Pre-Tax Income	($19.5)	($5.0)	($5.1)	($5.3)	($5.6)	($21.0)	($20.9)	($21.7)
Taxes	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	($0.0)	($0.0)
Net Income	($19.5)	($5.0)	($5.1)	($5.3)	($5.6)	($21.0)	($20.9)	($21.7)
Loss from Discontinued Operations	($1.2)	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Exchange differences on translation of foreign operations	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Comprehensive Loss	($20.8)	($5.0)	($5.1)	($5.3)	($5.6)	($21.0)	($20.9)	($21.7)
Reported EPS	($0.56)	($0.10)	($0.10)	($0.10)	($0.11)	($0.41)	($0.38)	($0.36)
Fully Diluted Shares	37.3	47.5	51.6	52.0	52.0	50.8	55.0	60.0

Source: David Bautz, PhD - Zacks Investment Research, Inc.

HISTORICAL STOCK PRICE



Source: Zacks Small Cap Research

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, David Bautz, PhD, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is a resident outside of Canada and is not an associated person of any Canadian registered adviser and/or dealer and, therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.